Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

69.65 EUR

-0.71 %

14,307 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

-0.71 %
+9.34 %
+9.43 %
+11.44 %
-1.62 %
+34.56 %
+41.65 %
+84.06 %
+520.21 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
9.83B EUR
Turnover
11.57M EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
15.01.2026
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2.
2026

Annual report '25

24.3.
2026

General meeting '26

23.4.
2026

Interim report Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Antti’s comment on the guidance: Inderes Orionilta vahva ohjeistus vuodelle 2026 - Inderes Ohjeistus ylitti odotuksemme erityisesti liikevaihdon osalta.
1/14/2026, 7:38 AM
by Ilkka
14
Nice outlook estimate. Operating profit at the midpoint is 15% above Inderes’ estimate. Revenue is 170 million above Inderes’.
1/14/2026, 7:04 AM
by Critter
14
This was a good overview of the long-term outlook: -One could say that until around the turn of the 2020s and 2030s, aided by Nubeqa and the expansion of its indications, massive amounts of money will be pouring into Orion from all sides. -Then the patents for this drug will expire...
1/19/2026, 8:02 AM
by PörssiPatruuna
11
Siltanen’s thoughts on Orion and Nubeqa’s strong momentum can also be heard in a new video filmed today. “The success of the cancer drug Nubeqa is like a story written in the stars. Orion estimates its share of Nubeqa sales will exceed the one billion euro mark by the end of the ...
1/16/2026, 2:23 PM
by Mikael Maijala
10
Siltanen has also produced a company report Orion published on Wednesday its outlook for 2026 and an estimate of the revenue potential for its blockbuster prostate cancer drug Nubeqa. The guidance exceeded our expectations in terms of revenue, and the midpoint of the earnings guidance...
1/15/2026, 5:18 AM
by Sijoittaja-alokas
9
Here is the data I was recalling from memory in the interview:
1/19/2026, 10:48 AM
by Antti Siltanen
7
Nubeqa’s patent protection is expected to remain in effect beyond 2030. Xtandi, which is Nubeqa’s direct competitor in the US prostate cancer market, currently holds the largest market share and is expected to face generic competition at the end of 2027, which will likely lead to...
1/23/2026, 12:55 PM
by AE
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.